On May 29, 2025, Athira Pharma, Inc. held its Annual Meeting, where shareholders elected directors and ratified Ernst & Young as auditors, with a significant approval for a reverse stock split. The stockholders authorized a split ratio of 5:1 to 20:1, to be determined by the Board.